

**Pharmacological study of therapeutic  
outcomes of carvedilol and carnitine  
combination in isoprenaline-induced  
myocardial infarction in rats**

**A Thesis Submitted in Partial Fulfillment of  
Ph.D. In Pharmaceutical Sciences  
(Pharmacology and Toxicology)**

**By  
Amira Mohammed Abdel-Rahim  
Mohammed Badr**

Assistant Lecturer of Pharmacology and Toxicology  
Faculty of Pharmacy  
Ain Shams University

**Under the supervision of**

**1- Amani E. Khalifa, Ph.D.**

Professor of Pharmacology and Toxicology, and Vice  
Dean for Post Graduate and Research, Faculty of  
Pharmacy, Ain Shams University.

**2- Ebtahal El-Demerdash Zaki, Ph.D.**

Professor of Pharmacology and Toxicology, Faculty of  
Pharmacy, Ain Shams University.

**3- Asser Ibrahim Ghoneim, Ph.D.**

Lecturer of Pharmacology and Toxicology, Damnhour  
University.

٢٠١١

١٤٣٢

Faculty of Pharmacy, Ain Shams University  
Pharmacology and Toxicology Department



دراسة دوائية للتأثيرات الناتجة من استخدام الكارفيديلول مع الكارنيتين  
لعلاج موت عضلة القلب الناتج عن استخدام أيزوبرينالين في الجرذان

رسالة مقدمة كأحد متطلبات الحصول على درجة الدكتوراة  
فى العلوم الصيدلية  
(تخصص أدوية و سموم)

المتقدم بالرسالة:

ص.م/ أميرة محمد عبد الرحيم محمد بدر  
مدرس مساعد بقسم الأدوية و السموم  
كلية الصيدلة  
جامعة عين شمس

تحت اشراف:

د أ.د/ أمانى امام خليفة  
أستاذ بقسم الأدوية و السموم, و وكيل الدراسات العليا و البحوث ,كلية  
الصيدلة , جامعة عين شمس.

د أ.م.د/ ابتهاج الدمرداش زكى  
أستاذ بقسم الأدوية و السموم, كلية الصيدلة , جامعة عين شمس.

د/ أسير ابراهيم غنيم  
مدرس بقسم الأدوية و السموم , كلية الصيدلة , جامعة دمنهور.

## **Abstract**

Mortality associated with acute myocardial infarction (AMI) is still a leading cause of death in both developing and developed countries. The effect of early treatment with  $\beta$ -blockers in reducing mortality and ischemic events after AMI is well known. The beta blocker; carvedilol; is an effective antianginal and antihypertensive agent and significantly limits infarct size in animal models. Carvedilol has previously been demonstrated to be beneficial in patients with AMI. However, the overall success of beta blockers is limited, and usually adverse reaction is clear. As such, it is important to evaluate new therapeutic modalities in addition to standard medical therapy.

Metabolic agents are a new class of drugs that directly modify the use of energy substrates in the heart, lessening ischaemic injury and improving cardiac performance during ischaemia. One of these metabolic agents is carnitine. Increasing evidences also demonstrate that oxidative stress plays an important role in experimental models of MI. Thymoquinone, the main volatile oil constituent of *Nigella sativa* seed, is reported to possess strong antioxidant properties. The protective effect of carvedilol-carnitine combination, and carvedilol-thymoquinone combination on myocardium was investigated using isoprenaline (ISO)-induced myocardial infarction (MI) model in rats.

Firstly, the effect of a single dose of drugs on ISO (250 mg/kg, S.C.)-induced MI was investigated; resembling acute MI treatment. Image analysis was carried out and levels of diagnostic marker enzymes in plasma, cardiac glutathione and lipid peroxides were measured. Injection of ISO caused animal mortality (46%), 60% infarction size, significant reduction in cardiac GSH level, and increased levels of diagnostic marker enzymes in plasma and lipid peroxidation in heart tissue.

Treatment with carvedilol, carnitine, or thymoquinone significantly prevented ISO-induced cardiac toxicity as evidenced by reduced mortality, reduced myocardial infarction size, decreased serum enzymes, and maintained myocardial antioxidant status at near normal status. While combination of carvedilol with either carnitine, or thymoquinone, didn't show significant difference from carvedilol group.

Secondly, the effect of daily administration of drug combination for 2 weeks started 24 hours following ISO injection (250 mg/kg S.C.) was investigated. Tissue pathology, heart weight, collagen content, and serum TNF- $\alpha$  were assessed. ISO induced focal area of fibrosis, increased heart weight, increased collagen content, but didn't affect TNF- $\alpha$  level. Thymoquinone didn't show any significant difference from ISO group. Carnitine, and carvedilol showed significant protection against post-MI change. Combination of carvedilol with thymoquinone didn't show significant difference

from carvedilol group, while, carnitine showed histopathological improvement when added to carvedilol.

From the results we conclude that, adding carnitine or thymoquinone to carvedilol didn't show additional beneficial effect compared to carvedilol alone against ISO-induced AMI. Regarding post MI remodeling, carvedilol-carnitine shows potential additive effect, while combination of carvedilol with thymoquinone didn't show beneficial effect compared to carvedilol alone. In addition, our results show that thymoquinone represents a potential cardioprotective agent against acute ISO-induced MI, while no protective effect was observed against post-MI remodeling.

# Contents

	<b>Page</b>
Abbreviations	<b>I</b>
List of tables	<b>IV</b>
List of figures	<b>V</b>
<b>AIM OF THE WORK</b>	<b>1</b>
<b>INTRODUCTION</b>	
- Myocardial infarction (MI)	<b>6</b>
- Pathogenesis of MI	<b>7</b>
- Diagnosis of MI	<b>17</b>
- Experimental models of MI.	<b>21</b>
- Management of MI	<b>25</b>
- Effectiveness of $\beta$ -blocker therapy for MI	<b>29</b>
- Carvedilol	<b>34</b>
- Carnitine	<b>43</b>

- Thymoquinone	59
<b>MATERIALS AND METHODS</b>	
- Design of the work	72
- Materials	78
- Methods	91
<b>RESULTS</b>	117
<b>DISCUSSION</b>	158
<b>SUMMARY AND CONCLUSIONS</b>	181
<b>REFERENCES</b>	187
الملخص العربى	



## **LIST OF FIGURES**

<b>Figure</b>		<b>Page</b>
<b>1</b>	<b>Reperfusion injury energy paradox.</b>	<b>14</b>
<b>2</b>	<b>Evaluation of the AMI patient ECG</b>	<b>18</b>
<b>3</b>	<b>The chemical structure of carvedilol.</b>	<b>31</b>
<b>4</b>	<b>Chemical Structure of carnitine.</b>	<b>41</b>
<b>5</b>	<b>The roles of the carnitine acyltransferases</b>	<b>45</b>
<b>6</b>	<b>Protective effects of carnitine on cardiac contractile efficiency</b>	<b>50</b>
<b>7</b>	<b>Morphological features of Nigella sativa plant</b>	<b>55</b>
<b>8</b>	<b>Chemical structures of TQ, Thymol and Dithymoquinone.</b>	<b>56</b>
<b>9</b>	<b>Detection of MI size using TTM stain.</b>	<b>86</b>
<b>10</b>	<b>Calibration curve of ALT.</b>	<b>90</b>
<b>11</b>	<b>Calibration curve of AST.</b>	<b>93</b>
<b>12</b>	<b>Standard curve of Glutathione</b>	<b>96</b>
<b>13</b>	<b>Standard calibration curve of TBARS</b>	<b>98</b>
<b>14</b>	<b>Standard calibration curve of protein</b>	<b>100</b>
<b>15</b>	<b>Calibration curve of hydroxyproline.</b>	<b>102</b>
<b>16</b>	<b>Standard calibration curve of TNF-<math>\alpha</math>.</b>	<b>105</b>
<b>17</b>	<b>Time response curve of ISO-induced CK elevation.</b>	<b>108</b>
<b>18</b>	<b>Dose response curve of ISO-induced MI.</b>	<b>109</b>
<b>19</b>	<b>Percentage of animals showing +ve CK elevation at different doses of ISO.</b>	<b>110</b>

<b>20</b>	<b>ECG of rat injected with ISO (250mg/kg) S.C. showing inverted T-wave, and rhythm disturbance.</b>	<b>112</b>
<b>21</b>	<b>ECG of rat injected with ISO (250mg/kg) S.C. showing ST-segment elevation.</b>	<b>112</b>
<b>22</b>	<b>histopathological examination of ISO (250mg/kg) treated rats.</b>	<b>114</b>
<b>23</b>	<b>Effect of drug treatment on ISO-induced infarction size.</b>	<b>120</b>
<b>24</b>	<b>Effect of drug treatment on ISO-induced CK elevation.</b>	<b>123</b>
<b>25</b>	<b>Effect of drug treatment on ISO-induced AST leakage.</b>	<b>126</b>
<b>26</b>	<b>Effect of drug treatment on ISO-induced ALT leakage.</b>	<b>129</b>
<b>27</b>	<b>Effect of drug treatment on ISO-induced GSH-depletion.</b>	<b>132</b>
<b>28</b>	<b>Effect of drug treatment on ISO-induced TBARS formation.</b>	<b>135</b>
<b>29</b>	<b>Effect of drug treatment on Heart weight to body weight%.</b>	<b>138</b>
<b>30</b>	<b>Histopathological examination of treated groups at 14 days post ISO (250 mg/kg) injection.</b>	<b>141</b>
<b>31</b>	<b>Histopathological examination of treated groups at 14 days post ISO (250 mg/kg) injection.</b>	<b>142</b>
<b>32</b>	<b>Effect of drug treatment on collagen synthesis measured as hydroxyproline content.</b>	<b>145</b>



## **LIST OF TABLES**

<b>Table</b>		<b>Page</b>
<b>1</b>	<b>Time response curve of ISO-induced CK elevation.</b>	<b>108</b>
<b>2</b>	<b>Dose response curve of ISO-induced MI</b>	<b>108</b>
<b>3</b>	<b>Effect of ISO injection on cardiac GSH and MDA levels</b>	<b>115</b>
<b>4</b>	<b>Effect of treatment modalities on ISO-induced mortality</b>	<b>117</b>
<b>5</b>	<b>Effect of treatment modalities on ISO-induced infarction size</b>	<b>119</b>
<b>6</b>	<b>Effect of treatment modalities on ISO-induced CK level elevation</b>	<b>122</b>
<b>7</b>	<b>Effect of treatment modalities on ISO-induced AST level elevation</b>	<b>125</b>
<b>8</b>	<b>Effect of treatment modalities on ISO-induced ALT level elevation</b>	<b>128</b>
<b>9</b>	<b>Effect of treatment modalities on ISO-induced GSH depletion</b>	<b>131</b>
<b>10</b>	<b>Effect of treatment modalities on ISO-induced lipid peroxidation</b>	<b>134</b>
<b>11</b>	<b>Effect of treatment modalities on heart weight to body weight%</b>	<b>137</b>
<b>12</b>	<b>Effect of treatment modalities on collagen synthesis measured as hydroxyproline content</b>	<b>144</b>
<b>13</b>	<b>Effect of treatment modalities on level of cardiac TNF- <math>\alpha</math></b>	<b>146</b>

## **Myocardial infarction**

Cardiovascular diseases form a major health concern in recent years (**Dhandapani et al., 2007**). It is the leading cause of mortality and a major cause of morbidity. Coronary heart disease (CHD) accounts for nearly half of all CVD deaths (**Nasir et al.; 2006**). CHD kills over 6.5 million people worldwide each year. CHD is a condition in which the vascular supply to the heart is impeded by atheroma, thrombosis or spasm of coronary arteries. This may impair the supply of oxygenated blood to cardiac tissue sufficiently to cause myocardial ischaemia which, if severe or prolonged, may cause the death of cardiac muscle cells; myocardial infarction (MI) (**Scott and Dwight, 2007**).

The consequences of MI are not benign. According to the statistics given by WHO in 2004 about 16.7 million people around the globe die of MI every year, which forms about one-third of the total global deaths. Among those who survive to reach hospital alive, approximately 12% of patients with ST segment elevation MI will die in the succeeding six months, and 13% of those with non-ST segment elevation MI. The frequency of new stroke is between 1.5–3%, and

rehospitalisation for a further MI is between 17–20% in the same time interval **(Fox, 2004)**. It is predicted that heart disease and stroke will become the leading cause of death and disability world-wide by the year 2020, with the number of fatalities projected to increase more than 20 million a year and to more than 24 million a year by 2030 **(Dhandapani et al., 2007)**.

### **1- Pathogenesis of MI**

#### **a- Pathogenesis of acute MI (AMI)**

MI is the acute condition of necrosis of the myocardium that occurs as a result of imbalance between coronary blood supply and myocardial oxygen demand, resulting in myocardial ischaemia and accumulation of waste metabolites **(Rajadurai and Prince, 2007 and Devika and Stanely Marinez Prince, 2008)**. MI can be regarded as a metabolic problem involving disruption of mitochondrial oxygen consumption and subnormal aerobic ATP resynthesis, resulting in ATP depletion, decrease of mitochondrial NADH oxidation, activation of glycolysis and accumulation of lactate and H<sup>+</sup> **(Wang et al., 2007)**. Membrane fragmentation and cell swelling are observed. Myofibril contracture bands are usually

considered characteristic (**Piper et al., 2006**). Necrosis is not the only aspect associated with irreversible lesions. Both necrosis and apoptosis are present in hearts subjected to permanent total ischaemia (**Monassier, 2008**).

MI is often due to atherosclerotic disease of the coronary arteries. It is a consequence of disruption of a vulnerable coronary artery plaque, complicated by intraluminal thrombosis, embolisation, and varying degrees of obstruction to perfusion. The severity of coronary arterial obstruction and the volume of affected myocardium determine the characteristics of clinical presentation (**Bertrand et al., 2002, Braunwald et al., 2002; and Van de Werf et al., 2003 and**). Additionally, coronary spasm, emboli, or dissection of the coronary artery are causes of infarction in the absence of occlusive atherosclerosis, and are reported in 5–10% of patients (**White and Chew, 2008**). Incomplete occlusion at the site of a disrupted arterial plaque may produce ischaemia or microinfarction, depending on the volume of myocardium affected and the extent of distal embolisation (**Van de Werf et al., 2003**).